8-K current report · filed Nov 17, 2026

SELLAS Life Sciences Group, Inc. (SLS) 8-K Current Report: November 17, 2026

Item 7.01Item 8.01Item EX-99.1SLS overview

Short answer

SELLAS Life Sciences Group, Inc. (SLS) filed an 8-K current report with the SEC on November 17, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Positive topline results from pivotal randomized Phase 3 REGAL trial of GPS in acute myeloid leukemia.

SELLAS Life Sciences Group, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Positive topline results from pivotal randomized Phase 3 REGAL trial of GPS in acute myeloid leukemia
  • Potential validation of GPS as an immunotherapeutic cancer vaccine for AML patients
  • Investor focus: detailed efficacy, safety, and regulatory implications in Exhibit 99.1

Item 8.01 · Other Events

  • Phase 3 REGAL met its primary overall-survival endpoint in relapsed/refractory AML
  • GPS reduced death risk 41%, hazard ratio 0.59, versus investigator’s-choice best available treatment
  • Median overall survival: 24.0 months with GPS versus 14.7 months with BAT
  • Statistical significance achieved, two-sided p=0.035, supporting potential regulatory and commercial value
  • Safety generally well tolerated, with mainly mild-to-moderate injection-site reactions and no new safety signals

Item EX-99.1 · Exhibit EX-99.1

  • Phase 3 REGAL met its primary endpoint, reducing AML death risk 41% versus best available treatment
  • Median overall survival: 24.0 months with GPS versus 14.7 months with BAT, hazard ratio 0.59, p=0.035
  • Trial enrolled 126 patients, supporting Phase 3 validation in AML patients unable to undergo stem cell transplantation
  • Company plans FDA discussions and preparations for an accelerated BLA filing in the first half of 2027
  • GPS safety profile remained consistent, with mostly mild-to-moderate injection-site reactions and no new safety signals

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other SELLAS Life Sciences Group, Inc. 8-K filings

Get the next SLS 8-K as it lands

Follow SLS for push alerts, or ask the research agent what this filing means.